Upcoming AACR Meeting Focuses on Recent Advances in Pancreatic Cancer Research

Pancreatic cancer is projected to become the second leading cause of cancer mortality in the United States by 2030. The prognosis for this disease remains grim: The overall five-year survival rate is lower than 10 percent, and this rate drops to less than 3 percent if the disease is identified after the cancer has metastasized, a stage at which more than half of pancreatic cancers are diagnosed.

Read More

Learning From the Immune System of Long-term Pancreatic Cancer Survivors

Pancreatic cancer is a deadly disease with a five-year survival rate of a mere 8.2 percent, according to statistics from the SEER database. Unfortunately, the last 30 years has not seen any significant improvement in survival for patients with this disease. Pancreatic cancer is projected to become the second leading cause of deaths due to cancer in the United States by 2030.

Read More

Advances in Pancreatic Cancer Research: Q&A With Christine Iacobuzio-Donahue, MD, PhD

This week, scientists from around the world will convene in Orlando, Florida, as the AACR hosts a conference titled Pancreatic Cancer: Advances in Science and Clinical Care. The conference will include discussion on the biological mechanisms of pancreatic cancer, drug development, epidemiology and risk factors, patient perspectives, and more.

Read More

New Nanotherapeutic Approved for Pancreatic Cancer

Yesterday, Onivyde, which is a nanotherapeutic form of the conventional chemotherapeutic irinotecan, was approved by the U.S. Food and Drug Administration (FDA) for use in combination with two other conventional chemotherapeutics, fluorouracil and leucovorin, to treat patients with advanced pancreatic cancer that has progressed despite treatment with gemcitabine-based chemotherapy.

Read More

On the Road to Better Pancreatic Cancer Treatments

Costas Lyssiotis, PhD, a 2013 Pancreatic Cancer Action Network-AACR Pathway to Leadership Grant recipient, is conducting research to understand the unique metabolism of pancreatic tumors and discover new therapeutic targets that can exploit the dependency of these tumors on the nutrients that fuel their growth.

Read More